Quantum Cyber (QUCY)
NASDAQ:QUCY
QUCY Stock Chart & Stats
$1.16
-$0.30(-6.42%)
At close: 4:00 PM EST
$1.16
-$0.30(-6.42%)
Day’s Range― - ―
52-Week Range$0.40 - $4.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)350.23K
Market Cap
$5.73M
Enterprise Value$2.77M
Total Cash (Recent Filing)$1.91M
Total Debt (Recent Filing)$3.09M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Apr 14, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding12,515,336
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.87
P/FCF Ratio-0.04
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue4.20
Enterprise Value/Gross Profit-50.81
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$918.00K
Bulls Say, Bears Say
Bulls Say
Clinical FeasibilityVery strong feasibility results for Mainz Biomed's pancreatic cancer diagnostic indicate the program can advance toward clinical validation, strengthening the diagnostic pipeline.
New Revenue OpportunityA successful pancreatic test would create a distinct revenue stream addressing an unmet clinical need, potentially enhancing long-term growth prospects.
Partnership And Licensing PotentialPromising pancreatic diagnostic data could attract collaboration or licensing interest from larger diagnostics firms, creating pathways to commercial development and non-dilutive funding.
Bears Say
Analyst Sentiment And Forecast UncertaintyAnalyst downgrades to Hold and removal of the prior price target reflect heightened caution about the company's strategic shift and uncertainty around future revenue assumptions.
Capital Structure And Dilution RiskA proposed private placement that would give a single investor control of most shares poses a major dilution risk and materially changes the company's capital structure.
Product Portfolio ContractionHalting development of the colorectal cancer screening platform removes an expected revenue source and narrows the company's product diversification.
Quantum Cyber News
QUCY FAQ
What was Quantum Cyber’s price range in the past 12 months?
Quantum Cyber lowest stock price was $0.40 and its highest was $4.43 in the past 12 months.
What is Quantum Cyber’s market cap?
Quantum Cyber’s market cap is $5.73M.
When is Quantum Cyber’s upcoming earnings report date?
Quantum Cyber’s upcoming earnings report date is Apr 14, 2026 which is in 7 days.
How were Quantum Cyber’s earnings last quarter?
Quantum Cyber released its earnings results on Sep 03, 2025. The company reported -$2.65 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.65.
Is Quantum Cyber overvalued?
According to Wall Street analysts Quantum Cyber’s price is currently Overvalued.
Does Quantum Cyber pay dividends?
Quantum Cyber does not currently pay dividends.
What is Quantum Cyber’s EPS estimate?
Quantum Cyber’s EPS estimate is -1.01.
How many shares outstanding does Quantum Cyber have?
Quantum Cyber has 12,515,336 shares outstanding.
What happened to Quantum Cyber’s price movement after its last earnings report?
Quantum Cyber reported an EPS of -$2.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Quantum Cyber?
Currently, no hedge funds are holding shares in QUCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quantum Cyber
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
QUCY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Ownership Overview
13.88% Insiders
<0.01% Mutual Funds
6.43% Other Institutional Investors
79.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---